Unichem Laboratories (NSE:UNICHEMLAB) Net Income From Continuing Operations: ₹3,048 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:UNICHEMLAB Unichem Laboratories Ltd NSE:UNICHEMLAB
73 GF Score
Price ₹524.25
GF Value ₹711.93
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Unichem Laboratories Net Income From Continuing Operations?

Unichem Laboratories NSE:UNICHEMLAB +1.00% 73 Net Income From Continuing Operations is ₹3,048 Mil as of Jun. 2026. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 73/100 and a GF Value™ of ₹711.93 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Unichem Laboratories's net income from continuing operations for the three months ended in Jun. 2026 was ₹415 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was ₹3,048 Mil.

Unichem Laboratories Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Unichem Laboratories's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unichem Laboratories Net Income From Continuing Operations Chart

Unichem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 219.69 -1,763.63 -849.60 1,545.90 2,923.80

Unichem Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -104.70 -118.90 2,642.90 109.10 414.70
NSE:UNICHEMLAB
73GF Score
Unichem Laboratories Ltd NSE:UNICHEMLAB
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unichem Laboratories Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,048 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of ₹3,048 Mil mean?
Unichem Laboratories (NSE:UNICHEMLAB) has a Net Income From Continuing Operations of ₹3,048 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Unichem Laboratories and its competitors.
Is Unichem Laboratories' Net Income From Continuing Operations too high?
Unichem Laboratories' current Net Income From Continuing Operations is ₹3,048 Mil. Overall, Unichem Laboratories has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' Net Income From Continuing Operations compare to ZTS?
Unichem Laboratories' Net Income From Continuing Operations of ₹3,048 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Unichem Laboratories and its competitors. Unichem Laboratories's current Net Income From Continuing Operations is ₹3,048 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹711.93, compared to a current price of ₹524.25 — trading 26.4% below its estimated fair value. The current Net Income From Continuing Operations is ₹3,048 Mil. Unichem Laboratories' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current Net Income From Continuing Operations is ₹3,048 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued. The current stock price of ₹524.25 is trading 26.4% below its estimated GF Value™ of ₹711.93. GuruFocus considers Unichem Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:UNICHEMLAB:

  • Net Income From Continuing Operations: ₹3,048 Mil
  • GF Value™: ₹711.93 vs. price of ₹524.25 (26.4% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Unichem Laboratories Business Description

Other Exchanges 506690:India
Address Off. S. V. Road, Unichem Bhavan, Prabhat Estate, Jogeshwari (West), Mumbai, MH, IND, 400 102
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
73GF Score

Get the complete analysis for NSE:UNICHEMLAB

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹524.25
Price
₹711.93
GF Value